Glaukos Q2 Sales Surge 50%, Guidance Raised to $700M on iDose TR and Epioxa Momentum
GKOS has more than doubled off its 52-week low of $73.16 on elevated volume (2.9× avg).
Summary
Glaukos delivered a standout Q2 with net sales of $185.6M, up 50% YoY, driven by 64% growth in U.S. glaucoma sales. Gross margins expanded to 82% GAAP and 85% non-GAAP, reflecting operating leverage. Management raised full-year 2026 revenue guidance to $680M-$700M, a significant jump from the prior $620M-$635M range, signaling confidence in the iDose TR and Epioxa launches. The company remains unprofitable but narrowed its non-GAAP net loss to $8.3M ($0.14/share) from $13.6M a year ago. With $289M in cash and no debt, the balance sheet supports continued investment in its pipeline. The stock is trading near a 52-week high, and this beat-and-raise quarter reinforces the growth narrative.
At the time of this announcement, GKOS was trading at $173.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $9.5B. The 52-week trading range was $73.16 to $166.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.